Advice
In the absence of a submission from the holder of the marketing authorisation:
lapatinib (Tyverb ®) 250 mg film-coated tablets is not recommended for use within NHS Scotland.
Indication under review: Treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor.
NICE (National Institute for Health and Clinical Excellence) is currently undertaking a multiple technology appraisal (MTA) that includes the use of lapatinib in this indication. However due to the significant time interval between product availability and the expected date of NICE guidance, not recommended advice has been issued.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice39KB (PDF)
Medicine details
- Medicine name:
- lapatinib (Tyverb)
- SMC ID:
- 768/12
- Indication:
- Breast cancer
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Superseded
- Date advice published
- 13 February 2012